Acura Pharmaceuticals, Inc ACUR
We take great care to ensure that the data presented and summarized in this overview for ACURA PHARMACEUTICALS, INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ACUR
Top Purchases
Top Sells
About ACUR
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.
Insider Transactions at ACUR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 02
2024
|
Bruce F Wesson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+4.33%
|
-
|
|
Jan 02
2024
|
Immanuel Thangaraj Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+10.05%
|
-
|
|
Jan 02
2024
|
William G Skelly Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.99%
|
-
|
|
Jan 02
2024
|
George K Ross Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+9.17%
|
-
|
|
Nov 20
2023
|
Albert W Brzeczko Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+7.6%
|
-
|
|
Nov 20
2023
|
Peter A Clemens Senior VP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+6.83%
|
-
|
|
Nov 20
2023
|
Robert B Jones President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+5.85%
|
-
|
|
Nov 20
2023
|
Robert A Seiser VP, Treasurer & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+8.36%
|
-
|
|
Jan 03
2023
|
Robert A Seiser VP, Treasurer & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+4.78%
|
-
|
|
Jan 03
2023
|
William G Skelly Director |
BUY
Exercise of conversion of derivative security
|
Direct |
66,666
+11.25%
|
-
|
|
Jan 03
2023
|
Immanuel Thangaraj Director |
BUY
Exercise of conversion of derivative security
|
Direct |
66,666
+14.36%
|
-
|
|
Jan 03
2023
|
Bruce F Wesson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
66,666
+7.76%
|
-
|
|
Jan 03
2023
|
George K Ross Director |
BUY
Exercise of conversion of derivative security
|
Direct |
66,666
+13.02%
|
-
|
|
Jan 03
2023
|
Albert W Brzeczko Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,000
+7.08%
|
-
|
|
Jan 03
2023
|
Peter A Clemens Senior VP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+7.33%
|
-
|
|
Jan 03
2023
|
Robert B Jones President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.65%
|
-
|
|
Aug 03
2022
|
Peter A Clemens Senior VP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
49,333
+9.58%
|
-
|
|
Aug 03
2022
|
Robert A Seiser VP, Treasurer & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
24,666
+6.12%
|
-
|
|
Aug 03
2022
|
Robert B Jones President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
63,666
+10.31%
|
-
|
|
Aug 03
2022
|
Albert W Brzeczko Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
43,333
+9.52%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 348K shares |
|---|